Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine for Visceral Adipose Tissue in Obesity and NAFLD
NCT05647915Phase 4Completed
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Jul 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of berberine in obesity, non-alcoholic fatty liver disease (NAFLD), sponsored by National Center for Cardiovascular Disease. Started Jul 2023; status: completed.
02
Drugs
berberine
03
Conditions
obesitynon-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05647915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647915.